Advancing Glioblastoma Treatment: Challenges and Opportunities of Immune Checkpoint Inhibition

References (34)

1. 1 Immune checkpoint inhibitors: recent progress and potential biomarkers [DOI]
2. 2 Hallmarks of response, resistance, and toxicity to immune checkpoint blockade [DOI]
3. 3 Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [DOI]
4. 4 Glioblastoma and Other Primary Brain Malignancies in Adults [DOI]
5. 5 Actively personalized vaccination trial for newly diagnosed glioblastoma [DOI]
6. 6 Molecular targeted therapy of glioblastoma [DOI]
7. 7 Multidimensional communication in the microenvirons of glioblastoma [DOI]
8. 8 Dynamics and specificities of T cells in cancer immunotherapy [DOI]
9. 9 Immune Checkpoint Inhibitors: Basics and Challenges [DOI]
10. 10 Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143 [DOI]
11. 11 Brain malignancies: Glioblastoma and brain metastases [DOI]
12. 12 Immune Microenvironment in Glioblastoma Subtypes [DOI]
13. 13 Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial [DOI]
14. 14 Advanced magnetic resonance imaging in glioblastoma: a review [DOI]
15. 15 Glioblastoma heterogeneity at single cell resolution [DOI]
16. 16 Immune Checkpoint in Glioblastoma: Promising and Challenging [DOI]
17. 17 Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma [DOI]
18. 18 Detection of circulating tumour cell clusters in human glioblastoma [DOI]
19. 19 Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial [DOI]
20. 20 Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial [DOI]
21. 21 Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial [DOI]
22. 22 Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study [DOI]
23. 23 Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade [DOI]
24. 24 Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma [DOI]
25. 25 NRG-BN002: Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma [DOI]
26. 26 A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol [DOI]
27. 27 Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study [DOI]
28. 28 A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma [DOI]
29. 29 Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results [DOI]
30. 30 Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study [DOI]
31. 31 Molecular Docking Analysis of Bacoside A with Selected Signalling Factors Involved in Glioblastoma [DOI]
32. 32 Glioblastoma Multiforme: Molecular Biology and Updated Systematic Review on Natural Extract and Phytochemical Efficacy In-vitro [DOI]
33. 33 Cancer stem cells in glioblastoma [DOI]
34. 34 Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Prediction of Radiotherapy Dose Distribution for Glioblastoma Using Convolutional Neural Network Model — shares topic coverage
• Microplastics as a Modulator of Oncogenic Gene Expression and Oxidative Stress in Glioblastoma Cancer — shares topic coverage
• Adoptive Cellular Immunotherapy in Glioblastoma: Mechanistic Insights, Clinical Progress, and Future Directions of CAR-T and TIL Therapies — shares topic coverage
• CBX2-Mediated Epigenetic Modulation Drives Proliferation in Gliomas: A Narrative Review — shares topic coverage
• Diagnostic Accuracy of Radiomics and Deep Learning for Differentiating Pseudoprogression from True Tumour Recurrence in Glioblastoma: A Systematic Review and Meta-analysis — shares topic coverage